Scott Platshon, Executive Vice President and Chief Business Officer of Zymeworks Inc. (NASDAQ:ZYME), filed a Form 4 on November 18, 2026, disclosing the vesting of restricted stock units and a mandatory sell-to-cover transaction on the same date.
Key Highlights
- RSU vesting: 37,037 shares of common stock were acquired on November 18, 2026, upon vesting of one third of RSUs originally granted on November 18, 2025, at a price of $0.
- Mandatory sell-to-cover: 15,292 shares were sold on November 18, 2026, at a weighted average price of $24.95, to satisfy tax withholding obligations and applicable fees under mandatory provisions in the RSU grant agreement.
- Price range: The 15,292 shares were sold in multiple transactions at prices ranging from $24.88 to $25.05, inclusive.
- Remaining direct ownership: Following the transactions, Platshon directly held 21,745 shares of common stock.
- Remaining RSUs: Platshon beneficially owned 74,074 RSUs following the reported transactions, held directly.
- Vesting schedule: The RSUs were granted November 18, 2025, and vest in three equal annual installments beginning November 18, 2026.
Zymeworks EVP Platshon Reports RSU Vesting and Tax Withholding Sale on November 18, 2026
According to the Form 4 filing, Scott Platshon, who serves as EVP and Chief Business Officer of Zymeworks Inc., reported two transactions in common stock on November 18, 2026. The first was an acquisition of 37,037 shares under transaction code "M," reflecting the vesting of one third of a restricted stock unit grant originally made on November 18, 2025. The shares were received at a price of $0, consistent with standard RSU conversion terms.
The filing disclosed that 15,292 of those shares were subsequently sold under transaction code "S" at a weighted average price of $24.95 per share. The filing explicitly states this sale "does not represent a discretionary sale by the Reporting Person" and was executed pursuant to mandatory "sell to cover" provisions in the applicable RSU grant agreement, solely to cover required taxes and applicable fees. The individual sales within this transaction occurred at prices ranging from $24.88 to $25.05, inclusive, according to the filing.
After both transactions, Platshon's direct beneficial ownership of common stock stood at 21,745 shares. In the derivative securities table, the filing reported that 37,037 RSUs were converted (transaction code "M") and that 74,074 RSUs remained beneficially owned directly following the transaction. Each RSU represents the contingent right to receive one share of common stock upon vesting. The remaining RSUs continue to vest in equal annual installments, with the next installments due on November 18, 2027, and November 18, 2028, per the vesting schedule described in the filing. The form was signed by Catherine Graham as Attorney-in-Fact on November 18, 2026.
What Was Disclosed
Zymeworks EVP and Chief Business Officer Scott Platshon disclosed a Form 4 covering an RSU vesting of 37,037 common shares and a mandatory sell-to-cover sale of 15,292 shares at a weighted average of $24.95, leaving him with 21,745 shares and 74,074 remaining RSUs.



Please wait processing your request...